Global Neurological Biomarkers Market – Industry Trends and Forecast to 2030

Analyse et taille du marché des biomarqueurs neurologiques

Selon l’OMS, en 2016, l’épilepsie représentait environ 13 millions d’années de vie corrigées de l’incapacité et plus de 0,5 % de la charge mondiale de morbidité. Cette augmentation de la fréquence des troubles neurologiques peut accroître la demande de biomarqueurs neurologiques, car ils aideront à détecter la maladie. De plus, les systèmes d’imagerie avancés contribuent au diagnostic précoce de diverses maladies tout en réduisant le taux de mortalité.

Français Data Bridge Market Research analyse que le marché des biomarqueurs neurologiques, qui était de 6,92 milliards USD en 2022, atteindrait 21,45 milliards USD d’ici 2030 et devrait connaître un TCAC de 13,4 % au cours de la période de prévision de 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l’épidémiologie des patients, l’analyse du pipeline, l’analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des biomarqueurs neurologiques

Définition du marché

Les biomarqueurs neurologiques sont des biomarqueurs considérés comme des critères d'évaluation et de calcul d'une méthode ou d'un symptôme pour acquérir une réponse pharmacologique à un traitement particulier. Ils sont largement utilisés pour identifier de nombreuses maladies, telles que la maladie de Parkinson, l'autisme et la dépression. Les types courants de biomarqueurs neurologiques sont l'imagerie, la génomique, la protéomique et la métabolomique.

Dynamique du marché mondial des biomarqueurs neurologiques

Conducteurs

• Progrès technologiques croissants des acteurs du marché

Les progrès récents dans le domaine des biomarqueurs, comme les signatures de biomarqueurs, rendent les maladies neurologiques plus faciles à traiter. Cela a permis un développement plus rapide des médicaments, des tests non invasifs et un diagnostic précoce. De plus, les biomarqueurs numériques offrent à de nombreuses sociétés pharmaceutiques des informations supplémentaires pour prendre des décisions concernant les essais cliniques. Le National Institute of Neurological Disorders and Stroke fournit des financements, tels que des subventions de développement et des accords de coopération, aux chercheurs effectuant des études associées à la découverte de biomarqueurs, à la validation analytique et à la validation clinique. Ainsi, ce facteur stimule la croissance du marché.

• Développement croissant de la médecine de précision

La recherche de biomarqueurs dans les maladies neurodégénératives est un domaine en pleine expansion dans le domaine de la médecine personnalisée. De nombreuses molécules ont été évaluées et associées à divers troubles neurodégénératifs. Cette évolution de la médecine de précision a eu un impact sur l'industrie biopharmaceutique. Différents acteurs, des sociétés biopharmaceutiques aux sociétés de diagnostic ayant plusieurs fonctions, telles que la recherche et le développement ou les opérations commerciales, observeront un énorme changement. Cela devrait avoir un impact positif sur la croissance du marché.

Opportunités

• Augmentation des fonds par les acteurs du marché

The wide presence of organizations providing funds at numerous stages of research is expected to drive market growth. For instance, the University of North Texas Health Science Center (HSC) was awarded about USD 45.5 million in funds from the National Institutes of Health (NIH) to support research associated with health disparities in Alzheimer's and brain aging. NIH is providing additional funds for biomarkers research for the current Health and Aging Brain Among Latino Elders (HABLE) study. Therefore, this factor boosts the market growth.

Restraints/Challenges

• High Startup Costs and Protracted Biomarker Development Cycles

The biomarkers vary in how well they perform in illness detection. Thus assessing biomarkers is a time-consuming process. Consequently, the validation process grows costly and time-consuming. The process and timetable for developing and validating biomarkers are thus comparable across various biomarker categories, with a few exceptions, as varied categories of biomarkers frequently share common development and validation process phases. Thus, this factor impedes market growth.

This neurological biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurological biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, Johnson & Johnson Services, Inc. entered into a strategic agreement with Enigma Biomedical Group to assess novel neuroimaging biomarkers-JNJ-64413739 and JNJ-64511070-to understand Alzheimer's disease and other dementias.

Global Neurological Biomarkers Market Scope

The neurological biomarkers market is segmented on the basis of product type, indication, imaging techniques, services, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Genomics Biomarker
• Proteomics Biomarker
• Imaging Biomarker
• Metabolomics Biomarker
• Others                                                          

Indication

• Spinal Muscular Atrophy
• Parkinson's Disease
• Schizophrenia
• Huntington's Disease
• Alzheimer's Disease
• Depression
• Multiple Sclerosis

Imaging Techniques  

• Transcranial Magnetic Stimulation
• Diffusion Tensor Imaging
• Conventional Structural MRI
• Functional Magnetic Resonance Imaging
• Positron Emission Tomography

 Services

• Sample Preparation
• Assay Development
• Biomarker Validation and Testing

End User

• Clinical Diagnostics
•  Pharmaceutical And Biotechnology Companies
• Research Organizations

Neurological Biomarkers Market Regional Analysis/Insights

The neurological biomarkers market is analyzed and market size insights and trends are provided by product type, indication, imaging techniques, services and end user as referenced above.

The countries covered in the neurological biomarkers market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the neurological biomarkers market because of the increase in healthcare expenditure and huge commercial performances of neurological diagnostics in the U.S. Furthermore, the growing product launches combined with the increase in demand for biomarkers are anticipated to impact the regional market positively.

Asia-Pacific is expected to witness significant growth because of the region's improvement in healthcare infrastructure and increase in disposable income. Also, an increasing number of clinical trials being performed in emerging countries, such as India and China, leads to market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The neurological biomarkers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for neurological biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the neurological biomarkers market. The data is available for historic period 2011-2021.

Competitive Landscape and Neurological Biomarkers Market Share Analysis

The neurological biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the neurological biomarkers market.

Some of the major players operating in the neurological biomarkers market are:

• Thermo Fisher Scientific (U.S.)
• QIAGEN (Netherlands)
• Agilent Technologies, Inc. (U.S.)
• McKesson Corporation (U.S)
• R1 RCM Inc., (U.S)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bio-Rad Laboratories, Inc. (U.S.)
• BGI (China), Quanterix (U.S.)
• bioMérieux Inc (U.S.)
• Neurosteer Inc. (U.S.)
• Advanced Brain Monitoring, Inc (U.S.)

SKU-50052